Summary
Gilead Sciences, Inc. (GILD) filed a Current Report on Form 8-K on May 25, 2016, to announce a key executive appointment. The company appointed Kevin Young as Chief Operating Officer, effective May 24, 2016. This appointment is significant as it brings in new leadership to a critical operational role within the company. Mr. Young's compensation package includes a substantial base salary, a target bonus, and significant equity awards in the form of stock options and performance-based restricted stock units. These awards are designed to align his incentives with the company's performance and shareholder value, underscoring the importance of his role in driving Gilead's future operational success.
Key Highlights
- 1Appointment of Kevin Young as Chief Operating Officer (COO) effective May 24, 2016.
- 2Mr. Young's annual base salary is set at $1,050,000.
- 3He is eligible for a target bonus opportunity of 95% of his annual base salary.
- 4Equity awards approved for Mr. Young include stock options valued at $1,750,000 (grant date fair value).
- 5Performance-based restricted stock units with a grant date fair value of $1,750,000 were also awarded.
- 6The actual number of shares for equity awards will be determined based on fair value on June 10, 2016.
- 7Stock options will have an exercise price equal to the closing price of Gilead's common stock on June 10, 2016, with a ten-year maximum term.